ACADIA Pharmaceuticals Company Profile (NASDAQ:ACAD)

About ACADIA Pharmaceuticals (NASDAQ:ACAD)

ACADIA Pharmaceuticals logoACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PD Psychosis). NUPLAZID is a selective serotonin inverse agonist (SSIA), preferentially targeting 5-HT2A receptors. The Company is conducting a Phase II trial, referred to as the SERENE Study, designed to examine the efficacy and safety of pimavanserin as a treatment for Alzheimer's disease (AD) Agitation. It is also conducting a Phase III, six-week, randomized, double-blind, placebo-controlled, multi-center, outpatient study, referred to as the ENHANCE-1 study, designed to examine the use of pimavanserin in patients with schizophrenia.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ACAD
  • CUSIP: N/A
  • Web: www.acadia-pharm.com
Capitalization:
  • Market Cap: $3.34 billion
  • Outstanding Shares: 122,046,000
Average Prices:
  • 50 Day Moving Avg: $31.63
  • 200 Day Moving Avg: $32.18
  • 52 Week Range: $20.68 - $42.49
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -13.41
  • P/E Growth: -0.33
Sales & Book Value:
  • Annual Revenue: $32.61 million
  • Price / Sales: 102.40
  • Book Value: $3.75 per share
  • Price / Book: 7.30
Profitability:
  • EBIDTA: ($309,030,000.00)
  • Net Margins: -4,427.79%
  • Return on Equity: -58.46%
  • Return on Assets: -54.70%
Debt:
  • Current Ratio: 15.42%
  • Quick Ratio: 15.31%
Misc:
  • Average Volume: 1.62 million shs.
  • Beta: 3.94
  • Short Ratio: 10.1
 

Frequently Asked Questions for ACADIA Pharmaceuticals (NASDAQ:ACAD)

What is ACADIA Pharmaceuticals' stock symbol?

ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."

How were ACADIA Pharmaceuticals' earnings last quarter?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) posted its earnings results on Tuesday, May, 9th. The company reported ($0.72) earnings per share for the quarter, topping analysts' consensus estimates of ($0.73) by $0.01. The company earned $15.30 million during the quarter, compared to analyst estimates of $15.17 million. ACADIA Pharmaceuticals had a negative return on equity of 58.46% and a negative net margin of 4,427.79%. During the same quarter in the prior year, the business earned ($0.45) earnings per share. View ACADIA Pharmaceuticals' Earnings History.

Where is ACADIA Pharmaceuticals' stock going? Where will ACADIA Pharmaceuticals' stock price be in 2017?

14 analysts have issued 1 year price targets for ACADIA Pharmaceuticals' shares. Their predictions range from $25.00 to $60.00. On average, they anticipate ACADIA Pharmaceuticals' share price to reach $43.00 in the next year. View Analyst Ratings for ACADIA Pharmaceuticals.

What are analysts saying about ACADIA Pharmaceuticals stock?

Here are some recent quotes from research analysts about ACADIA Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia. " (5/12/2017)
  • 2. Needham & Company LLC analysts commented, "Acadia reported $11.9M in 4Q16 Nuplazid sales, above our $9.0M estimate. Mgmt noted steady growth in number of prescribers, repeat prescribers, and new patients. Company also announced plan to expand sales force by 20 reps to address long-term care opportunity. There are no immediate plans to provide 2017 sales guidance. We believe stock is attractive given Nuplazid launch trajectory and likelihood for label expansion in long-term. Stock likely to be driven by sales in 2017 and Phase 2/3 results in other indications in 2018/ 2019. Acadia may be an attractive M&A target. BUY." (3/1/2017)

Who are some of ACADIA Pharmaceuticals' key competitors?

Who owns ACADIA Pharmaceuticals stock?

ACADIA Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BAKER BROS. ADVISORS LP (22.10%), FMR LLC (0.00%), Vanguard Group Inc. (0.00%), BlackRock Inc. (0.00%), OppenheimerFunds Inc. (0.00%) and Janus Capital Management LLC (2.82%). Company insiders that own ACADIA Pharmaceuticals stock include Bros Advisors Lp Baker, Edmund Harrigan, Glenn Baity, Leslie L Iversen, LP 14159 and Terrence O Moore. View Institutional Ownership Trends for ACADIA Pharmaceuticals.

Who sold ACADIA Pharmaceuticals stock? Who is selling ACADIA Pharmaceuticals stock?

ACADIA Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., JPMorgan Chase & Co., First Trust Advisors LP, State Street Corp, UBS Group AG, SG Americas Securities LLC, Pictet Asset Management Ltd. and Columbus Circle Investors. Company insiders that have sold ACADIA Pharmaceuticals stock in the last year include Glenn Baity and Terrence O Moore. View Insider Buying and Selling for ACADIA Pharmaceuticals.

Who bought ACADIA Pharmaceuticals stock? Who is buying ACADIA Pharmaceuticals stock?

ACADIA Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Elliott Management Corp, Point72 Asset Management L.P., Ameriprise Financial Inc., Vanguard Group Inc., Frontier Capital Management Co. LLC, Westfield Capital Management Co. LP and Edmond DE Rothschild Holding S.A.. Company insiders that have bought ACADIA Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker, Edmund Harrigan and LP 14159. View Insider Buying and Selling for ACADIA Pharmaceuticals.

How do I buy ACADIA Pharmaceuticals stock?

Shares of ACADIA Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of ACADIA Pharmaceuticals stock cost?

One share of ACADIA Pharmaceuticals stock can currently be purchased for approximately $27.36.

Analyst Ratings

Consensus Ratings for ACADIA Pharmaceuticals (NASDAQ:ACAD) (?)
Ratings Breakdown: 4 Hold Ratings, 10 Buy Ratings
Consensus Rating:Buy (Score: 2.71)
Consensus Price Target: $43.00 (57.16% upside)

Analysts' Ratings History for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/22/2017Rodman & RenshawReiterated RatingBuy$60.00LowView Rating Details
5/10/2017HC WainwrightReiterated RatingBuyLowView Rating Details
4/12/2017Jefferies Group LLCReiterated RatingBuy$47.00LowView Rating Details
4/5/2017Needham & Company LLCReiterated RatingBuy$49.00LowView Rating Details
2/7/2017Piper Jaffray CompaniesReiterated RatingOverweight$44.00N/AView Rating Details
2/2/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuy -> Buy$49.00 -> $48.00N/AView Rating Details
1/24/2017Cowen and CompanyReiterated RatingOutperform$42.00N/AView Rating Details
1/11/2017JPMorgan Chase & Co.Reiterated RatingBuyN/AView Rating Details
12/28/2016Leerink SwannReiterated RatingMarket Perform$29.00N/AView Rating Details
11/11/2016Goldman Sachs Group IncInitiated CoverageNeutral$28.00N/AView Rating Details
11/8/2016Bank of America CorpUpgradeNeutral -> Buy$35.00N/AView Rating Details
10/19/2016Roth CapitalReiterated RatingNeutral$25.00N/AView Rating Details
8/10/2016JMP SecuritiesReiterated RatingBuy$45.00N/AView Rating Details
8/5/2016AegisDowngradeBuy -> Hold$54.00 -> $41.00N/AView Rating Details
(Data available from 5/24/2015 forward)

Earnings

Earnings History for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Earnings by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Earnings History by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.73)($0.72)$15.17 million$15.30 millionViewListenView Earnings Details
2/28/2017Q416($0.65)($0.65)$9.05 million$12.00 millionViewListenView Earnings Details
11/7/2016Q316($0.56)($0.61)$2.90 million$5.30 millionViewListenView Earnings Details
8/4/2016Q216($0.49)($0.63)$0.71 million$0.97 millionViewListenView Earnings Details
5/5/2016Q116($0.42)($0.45)$0.22 millionViewListenView Earnings Details
2/29/2016Q415($0.38)($0.45)$0.02 millionViewListenView Earnings Details
11/5/2015Q315($0.40)($0.39)$0.05 million$0.04 millionViewListenView Earnings Details
8/6/2015Q215($0.33)($0.39)$0.06 millionViewListenView Earnings Details
5/7/2015Q115($0.25)($0.40)$0.09 millionViewListenView Earnings Details
2/26/2015Q414($0.26)($0.28)$0.08 million$0.05 millionViewListenView Earnings Details
11/10/2014Q3($0.12)($0.25)$0.02 millionViewListenView Earnings Details
8/5/2014Q2($0.17)($0.22)$0.10 million$0.03 millionViewListenView Earnings Details
5/6/2014Q1($0.13)($0.19)$0.50 million$0.03 millionViewListenView Earnings Details
2/27/2014Q4($0.14)($0.13)ViewListenView Earnings Details
8/6/2013Q2 2013($0.09)($0.11)$0.45 million$451.00 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.08)($0.08)$0.45 million$0.42 millionViewListenView Earnings Details
11/5/2012Q312($0.09)($0.04)$1.90 million$3.50 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for ACADIA Pharmaceuticals (NASDAQ:ACAD)
2017 EPS Consensus Estimate: ($2.37)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.75)($0.53)($0.64)
Q2 20172($0.71)($0.48)($0.60)
Q3 20172($0.72)($0.44)($0.58)
Q4 20172($0.71)($0.39)($0.55)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for ACADIA Pharmaceuticals (NASDAQ:ACAD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Insider Ownership Percentage: 21.65%
Institutional Ownership Percentage: 98.25%
Insider Trades by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Institutional Ownership by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Insider Trades by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/16/2017Terrence O. MooreEVPSell157,540$39.77$6,265,365.80View SEC Filing  
12/27/2016Glenn BaityEVPSell9,800$30.46$298,508.00View SEC Filing  
12/20/2016Glenn BaityEVPSell10,000$30.00$300,000.00View SEC Filing  
8/16/2016Edmund HarriganDirectorBuy1,000$32.97$32,970.00View SEC Filing  
8/10/2016Bros. Advisors Lp BakerDirectorBuy1,303,030$33.00$42,999,990.00View SEC Filing  
7/12/2016Glenn BaityEVPSell16,000$35.00$560,000.00View SEC Filing  
7/11/2016Glenn BaityEVPSell4,057$35.00$141,995.00View SEC Filing  
4/18/2016Leslie L IversenDirectorSell33,697$33.53$1,129,860.41View SEC Filing  
4/1/2016Bros. Advisors Lp BakerDirectorBuy1,449,090$27.08$39,241,357.20View SEC Filing  
1/7/2016L.P. 14159DirectorBuy2,586,206$29.00$74,999,974.00View SEC Filing  
11/11/2015Leslie L. IversenDirectorSell30,000$36.01$1,080,300.00View SEC Filing  
1/15/2015Michael T BorerDirectorSell27,973$33.02$923,668.46View SEC Filing  
1/14/2015Uli HacksellCEOSell30,000$33.98$1,019,400.00View SEC Filing  
12/15/2014Mary Ann GrayDirectorSell12,250$31.74$388,815.00View SEC Filing  
12/15/2014Uli HacksellCEOSell30,000$31.00$930,000.00View SEC Filing  
11/26/2014Michael T BorerDirectorSell15,000$30.05$450,750.00View SEC Filing  
11/26/2014Roger MillsCMOSell25,000$30.09$752,250.00View SEC Filing  
11/24/2014Uli HacksellCEOSell30,000$29.28$878,400.00View SEC Filing  
11/21/2014William Mcdowall WellsDirectorSell5,810$29.00$168,490.00View SEC Filing  
10/8/2014Uli HacksellCEOSell30,000$24.15$724,500.00View SEC Filing  
9/15/2014Laura BregeDirectorSell10,000$28.07$280,700.00View SEC Filing  
9/12/2014William Mcdowall WellsDirectorSell9,190$29.15$267,888.50View SEC Filing  
9/10/2014Uli HacksellCEOSell30,000$27.36$820,800.00View SEC Filing  
8/15/2014Uli HacksellCEOSell15,000$22.89$343,350.00View SEC Filing  
7/14/2014Uli HacksellCEOSell20,000$22.22$444,400.00View SEC Filing  
6/16/2014Uli HacksellCEOSell20,000$23.10$462,000.00View SEC Filing  
6/9/2014William Mcdowall WellsDirectorSell15,000$23.03$345,450.00View SEC Filing  
5/1/2014Torsten RasmussenDirectorSell32,857$20.03$658,125.71View SEC Filing  
4/15/2014Uli HacksellCEOSell25,000$17.75$443,750.00View SEC Filing  
4/4/2014Thomas AasenCFOSell15,000$22.48$337,200.00View SEC Filing  
4/4/2014Torsten RasmussenDirectorSell30,000$21.98$659,400.00View SEC Filing  
3/5/2014Bros. Advisors Lp BakerDirectorBuy526,316$28.50$15,000,006.00View SEC Filing  
2/26/2014Glenn BaityVPSell42,000$30.28$1,271,760.00View SEC Filing  
11/1/2013Torsten RasmussenDirectorSell37,692$23.00$866,916.00View SEC Filing  
11/1/2013Uli HacksellCEOSell15,000$23.24$348,600.00View SEC Filing  
10/10/2013Laura BregeDirectorSell10,000$21.63$216,300.00View SEC Filing  
10/1/2013Thomas H AasenCFOSell30,000$27.87$836,100.00View SEC Filing  
9/20/2013Roger MillsCMOSell35,965$25.01$899,484.65View SEC Filing  
9/12/2013Lester Ph KaplanDirectorSell66,356$22.90$1,519,552.40View SEC Filing  
9/10/2013Laura BregeDirectorSell46,153$22.80$1,052,288.40View SEC Filing  
9/3/2013Torsten RasmussenDirectorSell40,000$20.28$811,200.00View SEC Filing  
8/26/2013Mary Ann GrayDirectorSell15,000$20.68$310,200.00View SEC Filing  
8/13/2013Thomas AasenCFOSell60,000$20.15$1,209,000.00View SEC Filing  
8/13/2013Uli HacksellCEOSell52,771$20.14$1,062,807.94View SEC Filing  
6/5/2013Felix BakerDirectorBuy2,340,314$14.34$33,560,102.76View SEC Filing  
5/15/2013Felix BakerDirectorBuy1,993,000$12.50$24,912,500.00View SEC Filing  
4/12/2013Glenn BaityVPSell60,000$12.42$745,200.00View SEC Filing  
4/11/2013Thomas H AasenCFOSell40,000$11.06$442,400.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Latest Headlines for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Source:
DateHeadline
seekingalpha.com logoACADIA Pharmaceuticals (ACAD) Presents At Bank of America Merrill Lynch 2017 Health Care Conference - Slideshow
seekingalpha.com - May 24 at 3:17 PM
seekingalpha.com logoPositive Clinical Results Ahead For Acadia Pharmaceuticals - Seeking Alpha
seekingalpha.com - May 23 at 5:31 AM
americanbankingnews.com logoACADIA Pharmaceuticals Inc. (ACAD) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 22 at 12:25 PM
americanbankingnews.com logoACADIA Pharmaceuticals Inc. (ACAD) Stock Rating Reaffirmed by Rodman & Renshaw
www.americanbankingnews.com - May 22 at 10:54 AM
nasdaq.com logoLongwood Capital Partners LLC Buys ACADIA Pharmaceuticals Inc, Viveve Medical Inc, Biocryst ... - Nasdaq
www.nasdaq.com - May 16 at 5:40 AM
americanbankingnews.com logoACADIA Pharmaceuticals Inc. (ACAD) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - May 12 at 10:06 PM
seekingalpha.com logoAcadia Pharmaceuticals: Patience Will Be Rewarded - Seeking Alpha
seekingalpha.com - May 12 at 3:34 PM
americanbankingnews.com logoACADIA Pharmaceuticals Inc. (ACAD) to Post Q2 2017 Earnings of ($0.71) Per Share, Leerink Swann Forecasts
www.americanbankingnews.com - May 12 at 10:58 AM
americanbankingnews.com logoACADIA Pharmaceuticals Inc. (ACAD) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - May 11 at 7:36 AM
finance.yahoo.com logoEdited Transcript of ACAD earnings conference call or presentation 9-May-17 9:00pm GMT
finance.yahoo.com - May 10 at 8:27 PM
nasdaq.com logoOversold Conditions For Acadia Pharmaceuticals (ACAD) - Nasdaq
www.nasdaq.com - May 10 at 3:25 PM
finance.yahoo.com logoThe Acadia Sell-off Is Overdone
finance.yahoo.com - May 10 at 3:25 PM
americanbankingnews.com logoACADIA Pharmaceuticals Inc. (ACAD) Expected to Announce Quarterly Sales of $18.39 Million
www.americanbankingnews.com - May 10 at 11:54 AM
americanbankingnews.com logoACADIA Pharmaceuticals Inc. (ACAD) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - May 10 at 12:36 AM
reuters.com logoBRIEF-Acadia Pharmaceuticals reports Q1 revenue $15.3 million
www.reuters.com - May 9 at 8:19 PM
marketwatch.com logo10-Q: ACADIA PHARMACEUTICALS INC
www.marketwatch.com - May 9 at 8:19 PM
finance.yahoo.com logoACADIA Pharmaceuticals Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 9 at 8:19 PM
marketbeat.com logoAcadia reports 1Q loss
marketbeat.com - May 9 at 6:01 PM
finance.yahoo.com logoInvestor Network: ACADIA Pharmaceuticals Inc. to Host Earnings Call
finance.yahoo.com - May 9 at 3:17 PM
finance.yahoo.com logoACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference on May 16, 2017
finance.yahoo.com - May 8 at 11:27 AM
americanbankingnews.com logoZacks: Analysts Expect ACADIA Pharmaceuticals Inc. (ACAD) to Announce -$0.73 EPS
www.americanbankingnews.com - May 8 at 9:56 AM
finance.yahoo.com logoACADIA Pharmaceuticals to Announce First Quarter 2017 Financial Results on May 9, 2017 - Yahoo Finance
finance.yahoo.com - May 4 at 3:18 PM
finance.yahoo.com logoWhat to do when your biotechnology stock gets hit by takeover rumors
finance.yahoo.com - May 4 at 3:18 PM
zacks.com logoWhat's in the Cards for ACADIA (ACAD) this Earnings Season?
www.zacks.com - May 4 at 1:22 AM
businesswire.com logoACADIA Pharmaceuticals to Announce First Quarter 2017 Financial Results on May 9, 2017 - Business Wire (press release)
www.businesswire.com - May 2 at 3:21 PM
finance.yahoo.com logoACADIA Pharmaceuticals to Announce First Quarter 2017 Financial Results on May 9, 2017
finance.yahoo.com - May 2 at 3:21 PM
finance.yahoo.com logoWhat's in the Cards for ACADIA (ACAD) this Earnings Season?
finance.yahoo.com - May 2 at 3:21 PM
americanbankingnews.com logoACADIA Pharmaceuticals (ACAD) Getting Somewhat Positive Media Coverage, Study Shows
www.americanbankingnews.com - May 2 at 7:48 AM
finance.yahoo.com logoETFs with exposure to ACADIA Pharmaceuticals, Inc. : May 1, 2017
finance.yahoo.com - May 2 at 5:40 AM
americanbankingnews.com logoACADIA Pharmaceuticals Inc. (ACAD) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - May 1 at 9:17 AM
americanbankingnews.com logoACADIA Pharmaceuticals (ACAD) Getting Somewhat Negative News Coverage, Report Finds
www.americanbankingnews.com - April 29 at 8:42 AM
fool.com logoAcadia Pharmaceuticals May Just Be the Best Long-Term Play on the Alzheimer's Disease Treatment Market - Motley Fool
www.fool.com - April 27 at 3:36 PM
americanbankingnews.com logoSomewhat Favorable News Coverage Likely to Impact ACADIA Pharmaceuticals (ACAD) Share Price
www.americanbankingnews.com - April 26 at 9:19 AM
finance.yahoo.com logoAcadia Pharmaceuticals May Just Be the Best Long-Term Play on the Alzheimer's Disease Treatment Market
finance.yahoo.com - April 25 at 3:17 PM
americanbankingnews.com logoACADIA Pharmaceuticals Inc. (ACAD) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - April 25 at 12:33 PM
prnewswire.com logoHow These Biotech Stocks are Faring? -- ACADIA Pharma, Alexion Pharma, TG Therapeutics, and Esperion ... - PR Newswire (press release)
www.prnewswire.com - April 24 at 3:18 PM
finance.yahoo.com logoBiotech M&A Plunges as Trump Attacks Drug Companies
finance.yahoo.com - April 24 at 11:14 AM
americanbankingnews.com logoSomewhat Critical News Coverage Very Likely to Affect ACADIA Pharmaceuticals (ACAD) Stock Price
www.americanbankingnews.com - April 23 at 7:35 AM
americanbankingnews.com logoACADIA Pharmaceuticals (ACAD) Earns Media Sentiment Score of -0.06
www.americanbankingnews.com - April 20 at 7:31 AM
finance.yahoo.com logoETFs with exposure to ACADIA Pharmaceuticals, Inc. : April 19, 2017
finance.yahoo.com - April 19 at 3:15 PM
americanbankingnews.com logo Analysts Expect ACADIA Pharmaceuticals Inc. (ACAD) Will Announce Quarterly Sales of $13.82 Million
www.americanbankingnews.com - April 19 at 12:48 PM
americanbankingnews.com logoJefferies Group LLC Reiterates Buy Rating for ACADIA Pharmaceuticals Inc. (ACAD)
www.americanbankingnews.com - April 18 at 7:25 AM
americanbankingnews.com logoACADIA Pharmaceuticals (ACAD) Given Daily News Impact Score of 0.12
www.americanbankingnews.com - April 17 at 10:05 AM
americanbankingnews.com logo Analysts Expect ACADIA Pharmaceuticals Inc. (ACAD) Will Announce Earnings of -$0.73 Per Share
www.americanbankingnews.com - April 17 at 8:38 AM
americanbankingnews.com logoACADIA Pharmaceuticals Inc. (ACAD) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 14 at 10:35 PM
americanbankingnews.com logoACADIA Pharmaceuticals (ACAD) Earning Somewhat Positive Media Coverage, Analysis Finds
www.americanbankingnews.com - April 14 at 1:49 PM
americanbankingnews.com logoShort Interest in ACADIA Pharmaceuticals Inc. (ACAD) Decreases By 3.7%
www.americanbankingnews.com - April 13 at 7:22 AM
americanbankingnews.com logoJefferies Group LLC Reiterates "Buy" Rating for ACADIA Pharmaceuticals Inc. (ACAD)
www.americanbankingnews.com - April 12 at 3:15 PM
seekingalpha.com logoACADIA Pharmaceuticals (ACAD) Presents At 16th Annual Needham Healthcare Conference - Slideshow
seekingalpha.com - April 7 at 3:17 PM
nasdaq.com logoAcadia Pharmaceuticals Becomes Oversold (ACAD) - Nasdaq.com - Nasdaq
www.nasdaq.com - April 7 at 5:34 AM

Social

Chart

ACADIA Pharmaceuticals (ACAD) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by MarketBeat.com Staff